CLX heads into its July 31 earnings release with short sellers entrenched and options traders turning more defensive than they have been in months.
Short positioning is meaningfully elevated. Bears hold 9.7% of the free float short — a level that has climbed roughly 18% over the past month, reaching a new recent high. Days to cover runs just under five, meaning any sustained buying pressure would take time to absorb the existing short book. The borrow market, however, offers no friction to new shorts. Availability is ample at 311%, meaning there are more than three shares available to borrow for every one currently on loan. Cost to borrow is negligible at 0.54%, so bears face almost no carry cost holding into the print.
Options positioning reinforces the cautious tone. The put/call ratio has risen to 0.78 — nearly 1.8 standard deviations above its 20-day average of 0.67 — and the move has been directional and sustained: the ratio drifted consistently higher over the past two weeks from levels near 0.62. That pattern points to growing demand for downside protection as the report approaches, though the reading remains well below the 52-week high of 0.94.
Analysts heading into the quarter are broadly sceptical. The dominant theme in recent weeks has been target-price cuts with unchanged negative ratings — JPMorgan, Evercore ISI, and BNP Paribas all trimmed their numbers, while JPMorgan maintained Underweight with a $92 target, now below the current price of $97.41. The mean target across the consensus sits at $104, which implies modest upside, but the distribution is skewed: Barclays holds an Underweight rating with a target of just $86, and UBS and Citi both sit at Neutral with targets clustered near the current price. The fundamental concern is familiar — forward EPS estimates have moved sharply lower year-on-year, and the company's momentum profile is weak. The April print underlines the risk: CLX fell 8.1% on the day after the last quarterly release, and was still down 2.8% five days later.
One standout in the ownership data is Point72, which built a position of roughly 1.6 million shares — a new entry representing $1.2 million shares added in the March quarter. That is the only notably active positioning among the major holders in recent filings; BlackRock and State Street made only minor adjustments. On the insider side, a director bought $429,000 worth of shares in early May at $85.82, a trade that now sits in-the-money after the stock recovered, though two Group Presidents sold modest amounts in July at prices near the current level.
Thursday's print will test whether Clorox can show any improvement in its earnings trajectory — and whether the stock at $97 can hold its ground against a short book that has grown consistently all month and a Street that remains firmly in wait-and-see mode.
See the live data behind this article on ORTEX.
Open CLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
